In silico design of novel proton-pump inhibitors with reduced adverse effects

被引:1
作者
Li, Xiaoyi [1 ]
Kang, Hong [2 ]
Liu, Wensheng [3 ]
Singhal, Sarita [3 ]
Jiao, Na [1 ]
Wang, Yong [4 ]
Zhu, Lixin [3 ,5 ]
Zhu, Ruixin [1 ]
机构
[1] Tongji Univ, Dept Gastroenterol, Shanghai East Hosp, Sch Life Sci & Technol, Shanghai 200092, Peoples R China
[2] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, 7000 Fannin St, Houston, TX 77030 USA
[3] SUNY Buffalo, Digest Dis & Nutr Ctr, Dept Pediat, Buffalo, NY 14260 USA
[4] Beijing Univ Chinese Med, Basic Med Coll, Beijing 100029, Peoples R China
[5] SUNY Buffalo, Genome Environm & Microbiome Community Excellence, Buffalo, NY 14214 USA
基金
中国国家自然科学基金;
关键词
proton-pump inhibitor; adverse effect; pharmacological mechanism; toxicological mechanism; pKa calculation; DATABASE; PREDICTION; ENUMERATION; OMEPRAZOLE; PK(A); T3DB;
D O I
10.1007/s11684-018-0630-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The development of new proton-pump inhibitors (PPIs) with less adverse effects by lowering the pKa values of nitrogen atoms in pyrimidine rings has been previously suggested by our group. In this work, we proposed that new PPIs should have the following features: (1) number of ring II = number of ring I + 1; (2) preferably five, six, or seven-membered heteroatomic ring for stability; and (3) 1 < pKa1 < 4. Six molecular scaffolds based on the aforementioned criteria were constructed, and R groups were extracted from compounds in extensive data sources. A virtual molecule dataset was established, and the pKa values of specific atoms on the molecules in the dataset were calculated to select the molecules with required pKa values. Drug-likeness screening was further conducted to obtain the candidates that significantly reduced the adverse effects of long-term PPI use. This study provided insights and tools for designing targeted molecules in silico that are suitable for practical applications.
引用
收藏
页码:277 / 284
页数:8
相关论文
共 34 条
[1]   CancerResource: a comprehensive database of cancer-relevant proteins and compound interactions supported by experimental knowledge [J].
Ahmed, Jessica ;
Meinel, Thomas ;
Dunkel, Mathias ;
Murgueitio, Manuela S. ;
Adams, Robert ;
Blasse, Corinna ;
Eckert, Andreas ;
Preissner, Saskia ;
Preissner, Robert .
NUCLEIC ACIDS RESEARCH, 2011, 39 :D960-D967
[2]   Comparative Evaluation of in Silico pKa Prediction Tools on the Gold Standard Dataset [J].
Balogh, Gyoergy T. ;
Gyarmati, Benjamin ;
Nagy, Balazs ;
Molnar, Laszlo ;
Keserue, Gyoergy M. .
QSAR & COMBINATORIAL SCIENCE, 2009, 28 (10) :1148-1155
[3]  
Bickerton GR, 2012, NAT CHEM, V4, P90, DOI [10.1038/NCHEM.1243, 10.1038/nchem.1243]
[4]   ANGIOEDEMA AND URTICARIA ASSOCIATED WITH OMEPRAZOLE CONFIRMED BY DRUG RECHALLENGE [J].
BOWLBY, HA ;
DICKENS, GR .
PHARMACOTHERAPY, 1994, 14 (01) :119-122
[6]  
de Argila CM, 2005, DRUGS, V65, P97
[7]   Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem? [J].
Durand, Cheryl ;
Willett, Kristine C. ;
Desilets, Alicia R. .
CLINICAL MEDICINE INSIGHTS-GASTROENTEROLOGY, 2012, 5 :65-76
[9]   Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori [J].
Hagiwara, Tadashi ;
Mukaisho, Ken-ichi ;
Nakayama, Takahisa ;
Sugihara, Hiroyuki ;
Hattori, Takanori .
GUT, 2011, 60 (05) :624-630
[10]   HEALING AND RELAPSE OF SEVERE PEPTIC ESOPHAGITIS AFTER TREATMENT WITH OMEPRAZOLE [J].
HETZEL, DJ ;
DENT, J ;
REED, WD ;
NARIELVALA, FM ;
MACKINNON, M ;
MCCARTHY, JH ;
MITCHELL, B ;
BEVERIDGE, BR ;
LAURENCE, BH ;
GIBSON, GG ;
GRANT, AK ;
SHEARMAN, DJC ;
WHITEHEAD, R ;
BUCKLE, PJ .
GASTROENTEROLOGY, 1988, 95 (04) :903-912